evrazkarЕвразийский Кардиологический ЖурналEurasian heart journal2225-16852305-0748Евразийская ассоциация кардиологов10.38109/2225-1685-2013-1-19-30evrazkar-5536Research ArticleОРИГИНАЛЬНЫЕ СТАТЬИORIGINAL PAPERSКОМБИНИРОВАННАЯ ТЕРАПИЯ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ - НАШИ ОЖИДАНИЯCOMBINATION THERAPY OF ARTERIAL HYPERTENSION - OUR EXPECTATIONSОстроумоваОльга ДмитриевнаOstroumovaO. D.ostroumova.olga@mail.ruГусеваТатьяна ФедоровнаGusevaT. F.noemail@neicon.ruМосковский государственный медико-стоматологический университет им. А.И. Евдокимова; Первый московский государственный медицинский университет им. И. М. СеченоваРоссияMoscow State Medical and Dental University of A.I. EvdokimovRussian FederationМосковский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияMoscow State Medical and Dental University of A.I. EvdokimovRussian Federation201330032013011930Copyright © Остроумова О.Д., Гусева Т.Ф., 20132013Остроумова О.Д., Гусева Т.Ф.Ostroumova O.D., Guseva T.F.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.heartj.asia/jour/article/view/5536

В статье рассматриваются различные аспекты комбинированной терапии артериальной гипертонии. Приведены взаимодополняющие эффекты и преимущества комбинации блокаторов рецепторов к ангиотензину II и антагонистов кальция, описаны клинические ситуации, где ее использование является приоритетным. Подробно проанализированы имеющиеся литературные данные об эффективности и безопасности фиксированной комбинации телмисартана с амлодипином, в том числе у больных с ожирением, сахарным диабетом, тяжелой артериальной гипертонией.

The article is devoted to various aspects of the combined therapy of arterial hypertension. Given the complementary effects and advantages of the combination blockers receptors to angiotenzin II and calcium antagonists, are described clinical situation, where its use is a priority. Analyzed in detail the available literature data on the efficacy and safety of fixed combination telmisartan with amlodipine, including in patients with obesity, diabetes, severe arterial hypertension.

arterial hypertensionfixed combinationsangiotensin receptor blockers IItelmisartancalcium antagonistsamlodipineартериальная гипертонияфиксированные комбинацииблокаторы рецепторов к ангиотензину IIтелмисартанантагонисты кальцияамлодипинReferencesДиагностика и лечение артериальной гипертензии. Системные гипертензии 2010; 3: 5-26.Диагностика и лечение артериальной гипертензии. Системные гипертензии 2010; 3: 5-26.Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum, 2006; Том 8 (№ 11): 113-117.Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum, 2006; Том 8 (№ 11): 113-117.Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895906.Dahlof B., Sever P.S., Poulter N.R. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895906.Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Jamerson K., Weber M.A., Bakris G.L., et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26: 1282-9.Reboldi G., Angeli F., Cavallini C., et al. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens 2008; 26: 1282-9.Matchar D.B., Mccrory D.C., Orlando L.A., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.Matchar D.B., Mccrory D.C., Orlando L.A., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.Mistry N.B., Westheim A.S., Kjeldsen S.E. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006; 7: 575-581.Mistry N.B., Westheim A.S., Kjeldsen S.E. The angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trials. Expert Opin Pharmacother. 2006; 7: 575-581.Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002; 62: 443-462.Sica D.A. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002; 62: 443-462.Quan A., Chavanu K., Merkel J. et al. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs. 2006; 6: 103-113.Quan A., Chavanu K., Merkel J. et al. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs. 2006; 6: 103-113.Littlejohn T.W. III, Majul C.R., Olvera R. et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. 2009: 11: 207-213.Littlejohn T.W. III, Majul C.R., Olvera R. et al. Results of treatment with telmisartan-amlodipine in hypertensive patients. J Clin Hypertens. 2009: 11: 207-213.Littlejohn T.W. III, Majul C.R., Olvera R. et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a post-hoc subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. Postgrad Med. 2009; 121: 5-14.Littlejohn T.W. III, Majul C.R., Olvera R. et al. Telmisartan plus amlodipine in patients with moderate or severe hypertension: results from a post-hoc subgroup analysis of a randomized, placebo-controlled, parallel-group, 4 x 4 factorial study. Postgrad Med. 2009; 121: 5-14.Neldam S., Edwards C., Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27: 2145-53.Neldam S., Edwards C., Jones R. Switching patients with uncontrolled hypertension on amlodipine 10 mg to single-pill combinations of telmisartan and amlodipine: results of the TEAMSTA-10 study. Curr Med Res Opin 2011; 27: 2145-53.Neldam S., Edwards C., Lang M., Jones R. for The TEAMSTA-5 and TEAMSTA-10 Investigators. Long-Term Tolerability and Efficacy of SinglePill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Current Therapeutic Research, Clinical and Experimental 2012,73 (1/2): 65-84.Neldam S., Edwards C., Lang M., Jones R. for The TEAMSTA-5 and TEAMSTA-10 Investigators. Long-Term Tolerability and Efficacy of SinglePill Combinations of Telmisartan 40-80 mg Plus Amlodipine 5 or 10 mg in Patients Whose Blood Pressure Was Not Initially Controlled by Amlodipine 5-10 mg: Open-Label, Long-Term Follow-Ups of the TEAMSTA-5 and TEAMSTA-10 Studies. Current Therapeutic Research, Clinical and Experimental 2012,73 (1/2): 65-84.Neutel J., Mancia G., Black H., et al. Single-Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. Journal of Clinical Hypertension (Greenwich), 2012; 14 (4): 206 - 215 (ERRATUM The Journal of Clinical Hypertension doi: 10.1111/jch.12025).Neutel J., Mancia G., Black H., et al. Single-Pill Combination of Telmisartan/Amlodipine in Patients With Severe Hypertension: Results From the TEAMSTA Severe HTN Study. Journal of Clinical Hypertension (Greenwich), 2012; 14 (4): 206 - 215 (ERRATUM The Journal of Clinical Hypertension doi: 10.1111/jch.12025).Sharma A.M., Bakris G., Neutel J.M., et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012; 34: 537-51.Sharma A.M., Bakris G., Neutel J.M., et al. Single-pill combination of telmisartan/amlodipine versus amlodipine monotherapy in diabetic hypertensive patients: an 8-week randomized, parallel-group, double-blind trial. Clin Ther. 2012; 34: 537-51.Guthrie R.M., Dahlof B., Jamerson K.A., et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011; 27: 1995-2008.Guthrie R.M., Dahlof B., Jamerson K.A., et al. Efficacy and tolerability of telmisartan plus amlodipine in added-risk hypertensive patients. Curr Med Res Opin 2011; 27: 1995-2008.White W.B., Littlejohn T.W., Majul C.R., et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010; 15: 205-12.White W.B., Littlejohn T.W., Majul C.R., et al. Effects of telmisartan and amlodipine in combination on ambulatory blood pressure in stages 1-2 hypertension. Blood Press Monit 2010; 15: 205-12.

The authors declare that there are no conflicts of interest present.